1. Agarwal, J.C., Nath, C, Gupta, G.P., Bhargava, K.P. and Shanker, K. (1981) Anti-Parkinsonian and anticonvulsant activity of some silyl substituted dopamine derivatives.Pharmacological Research Commumications,13, 937–947.
2. Aminoff, M.J. (1994) Treatment of Parkinson’s disease.Western Journal of Medicine,161, 303–308.
3. Archer, T. and Fredriksson, A. (1999) Effects of acute/chronic, subthreshold/threshold doses of L-Dopa in MPTP-treated mice: I Influence of competitive and noncompetitive NMDA antagonists. In: Palomo, T., Beninger, R.J. and Archer, T. (Eds.)Interactive Monoaminergic Disorders. Editorial Sintesis, Madrid, pp. 573–606.
4. Archer, T., Fredriksson, A., Jonsson, G., Lewander, T., Mohammed, A.K., Ross, S.B. and Söderberg, U. (1986) Central noradrenaline depletion antagonizes aspects of d-amphetamine-induced hyperactivity in the rat.Psycho-pharmacology (Ber/.),88, 141–146.
5. Archer, T., Bassen, M., Peters, D., Luthman, J. and Fredriksson, A. (1996) Dopaminergic-glutamatergic balance in the forebrain: functional studies of movement disorders in rats and mice. In Beninger, R.J., Palomo, T. and Archer, T. (Eds.)Dopamine Disease States. Madrid University Press, Madrid, pp. 117–154.